KURA - Kura teams up with Illumina for a companion diagnostic for lead therapy

In a regulatory filing, Kura Oncology (KURA) announces that on January 04, it entered into a collaboration agreement, with Illumina (ILMN) for a companion diagnostic test for use with the company’s lead product candidate, tipifarnib.The agreement tided to a project schedule will require Illumina to develop and commercialize an assay as a companion diagnostic test for use with tipifarnib to identify head and neck squamous cell carcinoma (‘HNSCC”) patients with an HRAS mutation.The collaboration covers the United States, the United Kingdom, major European markets, and other countries as mutually agreed by the two parties.Currently, Kura is advancing a global, multi-center, open-label, non-comparative registration-directed clinical trial of tipifarnib in HRAS mutant HNSCC.

For further details see:

Kura teams up with Illumina for a companion diagnostic for lead therapy